anurajms/meta_analysis huggingface dataset:
outcomes:
Physical training for asthma
1. Quality of Life 2. Walking Distance Test 3. Lung function test
outcomes:
Holding chambers (spacers) versus nebulisers for beta‐agonist treatment of acute asthma
1. Hospitalization
outcomes:
Inspiratory muscle training for asthma
1. Forced Expiratory Volume 1 2. Dyspnea 3. Asthma exacerbation 4. Muscle Finding
outcomes:
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
1. Pneumonia 2. Death 3. Hospitalization 4. COPD Exacerbation
outcomes:
Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children
1. Hospitalization
outcomes:
Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
1. Pneumothorax 2. Bradycardia 3. Weaning From Mechanically Assisted Ventilation 4. Cardiac Arrest 5. Death 6. Hypoxia 7. Low Blood Pressure
outcomes:
Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease
1. Pneumonia 2. Death 3. Hospitalization 4. COPD Exacerbation
outcomes:
Drug therapy for obstructive sleep apnoea in adults
1. Sleep Apnea Assessment 2. Ess - Epworth Sleepiness Scale 3. Sleepiness 4. Apnoea Hypopnoea Index
outcomes:
Physician advice for smoking cessation
1. Smoking cessation
outcomes:
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
1. Serious Adverse Event 2. Normal Growth 3. Death 4. Hospitalization 5. Adverse Event 6. Asthma exacerbation
outcomes:
Swimming training for asthma in children and adolescents aged 18 years and under
1. Quality Of Life Scale 2. Quality of Life 3. Hospitalization 4. Asthma exacerbation
outcomes:
Inhaled corticosteroids for subacute cough in children
1. Treatment Failure
outcomes:
Lung protective ventilation strategy for the acute respiratory distress syndrome
1. Death
outcomes:
Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome
1. Death 2. Mechanical ventilation
outcomes:
Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
1. Quality of Life 2. Asthma Finding 3. Medication adherence 4. Lung function test 5. Asthma exacerbation 6. Adverse Event
outcomes:
Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults
1. Withdrawn From Research Study 2. Emergency Care 3. Serious Adverse Event 4. Medication Dose Changed 5. Body Height 6. Peak Expiratory Flow Rate 7. Asthma exacerbation
outcomes:
Psychosocial interventions for reducing antipsychotic medication in care home residents
1. Traumatic Injury 2. Falls 3. Cognitive function 4. Dementia Symptoms - Behavioral And Psychiatric 5. Death 6. On Psychotropic Medication 7. Hospitalization
outcomes:
Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings
1. Physical Restraint
outcomes:
Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia
1. Aggressive Behavior 2. Agitated 3. Adverse Event
outcomes:
Cognitive rehabilitation for people with mild to moderate dementia
1. Functional ability 2. Canadian Occupational Performance Measure 3. Direct Measure of Training
outcomes:
Personally tailored activities for improving psychosocial outcomes for people with dementia in long‐term care
1. Healthcare costs 2. Expression Of Emotions 3. Social Behavior 4. Dementia Symptoms - Behavioral And Psychiatric 5. Quality of Life 6. Mood 7. Carer Able To Cope 8. On Psychotropic Medication 9. Adverse Event
outcomes:
Cognitive stimulation to improve cognitive functioning in people with dementia
1. Activities of Daily Living 2. Cognitive function 3. Social Interaction 4. Dementia Symptoms - Behavioral And Psychiatric 5. Behavior 6. Quality of Life 7. Mood 8. Carer Able To Cope
outcomes:
Non‐pharmacological interventions for sleep disturbances in people with dementia
1. Functional Performance And Activity 2. Sleep Finding 3. Dementia Symptoms - Behavioral And Psychiatric 4. Quality of Life 5. Patient compliance 6. Finding Relating To Institutionalization
outcomes:
Pharmacological interventions for the treatment of disordered and problem gambling
1. Compulsive Gambling 2. Yale Brown Obsessive Compulsive Scale adapted for Pathological Gambling 3. Clinical Global Impression 4. South Oaks Gambling Screen
outcomes:
Interventions for preventing and reducing the use of physical restraints of older people in general hospital settings
1. Adverse Event 2. Physical Restraint
outcomes:
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia
1. Cognitive function 2. Ischemic Stroke 3. Death 4. Intracranial Hemorrhage 5. Physical Functional Dependency 6. Adverse Event 7. Dementia
outcomes:
Algorithm‐based pain management for people with dementia in nursing homes
1. Serious Adverse Event 2. Pain 3. Challenging Behavior
outcomes:
Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD)
1. Withdrawn From Research Study 2. Posttraumatic Stress Disorder
outcomes:
Non‐pharmacological interventions for preventing delirium in hospitalised non‐ICU patients
1. Delirium 2. All Cause Mortality 3. Death 4. Dementia
outcomes:
Multi‐domain interventions for the prevention of dementia and cognitive decline
1. Montreal Cognitive Assessment 2. Cambridge Cognitive Examination 3. Adverse Event 4. Mini-mental State Examination 5. Activities of Daily Living 6. Repeatable Battery for the Assessment of Neuropsychological Status 7. Quality of Life 8. Alzheimer's Disease Assessment Scale-cognitive subscale 9. Death 10. Cognitive Disorder 11. Alzheimer'a Disease Assessment Scale 12. Mild Cognitive Disorder 13. Dementia
outcomes:
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder
1. Headache 2. Dry Mouth 3. Abnormal Urination 4. Agitated 5. Low Blood Pressure 6. Adverse Event 7. Dizziness 8. Withdrawn From Research Study 9. Vomiting 10. Seizure 11. Anxiety 12. Constipation 13. Sleepiness 14. Hypertensive disorder 15. Bipolar Disorder In Remission 16. Depressive Disorder In Remission 17. Tremor 18. Delusions 19. Depression 20. Nausea 21. Dissociative Disorder 22. Therapeutic Response 23. Insomnia 24. Hallucinations 25. Mania 26. Diarrhoea 27. Withdrawal Due To Adverse Events 28. Hypomania
outcomes:
Lamotrigine in the maintenance treatment of bipolar disorder
1. Treatment Withdrawal 2. Disease Recurrence 3. Adverse Event
outcomes:
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder
1. Withdrawn From Research Study 2. Depression 3. Efficacy 4. Remission 5. Adverse Event
outcomes:
Enteral tube feeding for people with severe dementia
1. Pressure ulcer 2. Quality of Life
outcomes:
Magnetic seizure therapy for treatment‐resistant depression
1. Treatment-resistant depression 2. Symptom severity 3. Cognitive impairment
outcomes:
Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia
1. Blood pressure measurement 2. Cognitive function 3. Quality of Life 4. Adverse Event 5. Dementia
outcomes:
Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety disorders in adults
1. Relapse 2. Treatment Success 3. Drug Withdrawal 4. Adverse Event
outcomes:
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis
1. Cognitive function 2. Clinical Finding 3. Alzheimer'a Disease Assessment Scale 4. Clinical Global Impression 5. Adverse Event 6. Activities Of Daily Living Assessment
outcomes:
Antidepressant treatment for postnatal depression
1. Depressive Disorder In Remission 2. Adverse Event 3. Therapeutic Response
outcomes:
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
1. Withdrawn From Research Study 2. Cognitive function 3. Functional Performance And Activity 4. Dementia Symptoms - Behavioral And Psychiatric 5. Adverse Event 6. Finding Relating To Institutionalization
outcomes:
Pharmacological interventions for self‐harm in adults
1. Self-harm
outcomes:
Remotely delivered information, training and support for informal caregivers of people with dementia
1. Quality of Life 2. Mood 3. Depression 4. Carer Able To Cope 5. Anxiety
outcomes:
Personally tailored activities for improving psychosocial outcomes for people with dementia in community settings
1. Cohen-Mansfield Aggression Inventory 2. Challenging Behavior 3. Quality of Life 4. Euroqol
outcomes:
Behavioural activation therapy for depression in adults with non‐communicable diseases
1. Treatment Withdrawal 2. Quality of Life 3. Assessment Using Social Functioning Scale 4. Anxiety Symptoms 5. Therapeutic Response 6. Clinical Improvement
outcomes:
Avatar Therapy for people with schizophrenia or related disorders
1. Withdrawn From Research Study 2. Quality of Life 3. Anxiety 4. Mental State Finding 5. Clinical Global Impression of Change 6. Global Assessment 7. Adverse Event
outcomes:
Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia
1. Activities of Daily Living 2. Cognitive function 3. Quality of Life 4. Death 5. Adverse Event 6. Dementia
outcomes:
Simulated presence therapy for dementia
1. Dementia Symptoms - Behavioral And Psychiatric 2. Quality of Life 3. Depression
outcomes:
Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life
1. Cognitive function 2. Quality of Life
outcomes:
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease
1. Activities of Daily Living 2. Cognitive function 3. Quality of Life 4. Depression 5. Carer Able To Cope 6. Indifference/Apathy 7. Anxiety 8. Alzheimer'a Disease Assessment Scale 9. Adverse Event 10. Mini-mental State Examination
outcomes:
Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery
1. Activities of Daily Living 2. Cognitive function 3. Pain 4. Behavior 5. Quality of Life 6. Safety Finding 7. Death 8. Hospitalization
outcomes:
Psychosocial interventions for people with both severe mental illness and substance misuse
1. Withdrawn From Research Study 2. Substance Use 3. Death 4. Mental State Finding 5. Global Assessment 6. Life satisfaction 7. Alcohol Use
outcomes:
Couple and family therapies for post‐traumatic stress disorder (PTSD)
1. Treatment Withdrawal 2. Violence 3. Aggressive Behavior 4. Posttraumatic Stress Disorder 5. Depression 6. Anxiety 7. Social functioning 8. Social Adjustment Scale
outcomes:
Present‐centered therapy (PCT) for post‐traumatic stress disorder (PTSD) in adults
1. Treatment Withdrawal 2. Posttraumatic Stress Disorder 3. Therapeutic Response
outcomes:
Cerebrolysin for vascular dementia
1. Cognitive function 2. Quality of Life 3. Death 4. Caregiver Role Strain 5. Adverse Event 6. Functional ability
outcomes:
Pharmacological interventions for the treatment of delirium in critically ill adults
1. Coma 2. Delirium 3. Prolonged QT Interval 4. Length Of Stay 5. Mechanical ventilation
outcomes:
Multiple session early psychological interventions for the prevention of post‐traumatic stress disorder
1. Treatment Withdrawal 2. Posttraumatic Stress Disorder 3. Depressive symptoms 4. Anxiety 5. Functional ability
outcomes:
Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses
1. Duration Of Hospital Stay 2. Catatonia 3. Adverse Event 4. Patient-Reported Outcome
outcomes:
Antidepressants plus benzodiazepines for adults with major depression
1. Withdrawn From Research Study 2. Severe Anxiety (panic) 3. Severe Major Depression 4. Withdrawal Due To Adverse Events
outcomes:
Psychological therapies for preventing seasonal affective disorder
1. Treatment Withdrawal 2. Seasonal Affective Disorder 3. Adverse Event
outcomes:
Interventions for preventing delirium in older people in institutional long‐term care
1. Delirium 2. Activities of Daily Living 3. Cognitive function 4. Healthcare costs 5. Quality of Life 6. Death 7. Adverse Event 8. Dementia
outcomes:
Benzodiazepines versus placebo for panic disorder in adults
1. Treatment Withdrawal 2. Panic Disorder With Agoraphobia And Panic Attacks In Full Remission 3. Panic Attack 4. Withdrawal Due To Adverse Events 5. Panic Disorder Without Agoraphobia With Panic Attacks In Full Remission 6. Therapeutic Response 7. Clinical Improvement
outcomes:
Cognitive training for people with mild to moderate dementia
1. Activities of Daily Living 2. Cognitive function 3. Dementia Symptoms - Behavioral And Psychiatric 4. Quality of Life 5. Mood 6. Disease Condition Finding
outcomes:
Memantine for dementia
1. Activities of Daily Living 2. Cognitive function 3. Healthcare costs 4. Dementia Symptoms - Behavioral And Psychiatric 5. Quality of Life 6. Carer Able To Cope 7. Clinical Finding 8. Clinical Global Impression 9. Adverse Event 10. Finding Relating To Institutionalization
outcomes:
Electroconvulsive therapy for treatment‐resistant schizophrenia
1. Evaluating Response To Treatment 2. Cognitive function 3. Death 4. Hospitalization 5. Patient Satisfaction
outcomes:
Second‐generation antidepressants for preventing seasonal affective disorder in adults
1. Headache 2. Seasonal Affective Disorder 3. Insomnia 4. Diarrhea 5. Nausea 6. Withdrawal Due To Adverse Events 7. Adverse Event
outcomes:
Computerised cognitive training for preventing dementia in people with mild cognitive impairment
1. Cognitive function 2. Quality of Life
outcomes:
Computerised cognitive training for maintaining cognitive function in cognitively healthy people in midlife
1. Cognitive function 2. Quality of Life
outcomes:
Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia
1. Quality Of Life Scale 2. Withdrawn From Research Study 3. Relapse 4. Costs and Cost Analysis 5. Social and Occupational Functioning Assessment Scale 6. Patient Satisfaction Score 7. Quality of Life 8. Global Assessment 9. Functional ability 10. Adverse Event 11. Carer-Reported Outcome
outcomes:
Interventions for preventing intensive care unit delirium in adults
1. Delirium 2. Cognitive function 3. Intensive care unit delirium 4. Ventilator Finding 5. Death 6. Duration Of Hospital Stay 7. Intensive Care 8. Cognitive impairment
outcomes:
Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia
1. Costs and Cost Analysis 2. Hospitalization 3. Mental State Finding 4. Global Assessment 5. Adverse Event 6. Functional ability
outcomes:
Valproate preparations for agitation in dementia
1. Cognitive function 2. Functional Performance And Activity 3. Agitated 4. Carer Able To Cope 5. Clinical Finding 6. Clinical Global Impression 7. Adverse Event
outcomes:
Antidepressants for treating depression in dementia
1. Cognitive function 2. Depression
outcomes:
Environmental and behavioural modifications for improving food and fluid intake in people with dementia
1. Body Mass Index 2. Activities of Daily Living 3. Cognitive function 4. Energy 5. Body weight 6. Behavior 7. Malnutrition 8. Quality of Life 9. Food And Drink Intake 10. Nutritional status
outcomes:
Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings
1. Delirium 2. Cognitive function 3. Duration of Symptom 4. Healthcare costs 5. Quality of Life 6. Death 7. Hospitalization 8. Adverse Event 9. Finding Relating To Institutionalization
outcomes:
Donepezil for dementia due to Alzheimer's disease
1. Activities of Daily Living 2. Cognitive function 3. Healthcare costs 4. Behavior 5. Quality of Life 6. Death 7. Carer Able To Cope 8. Clinical Global Impression 9. Adverse Event 10. Finding Relating To Institutionalization
outcomes:
Couple therapy for depression
1. Treatment Withdrawal 2. Depressive symptoms 3. Withdrawal Due To Adverse Events
outcomes:
Processed electroencephalogram and evoked potential techniques for amelioration of postoperative delirium and cognitive dysfunction following non‐cardiac and non‐neurosurgical procedures in adults
1. Postoperative Confusion 2. Cognitive impairment
outcomes:
Antidepressants for preventing postnatal depression
1. Postpartum Depression 2. Breastfeeding 3. Adverse Event 4. Patient Satisfaction
outcomes:
Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia
1. Withdrawn From Research Study 2. Mental State Finding 3. Tardive dyskinesia 4. Adverse Event 5. Social inclusion
outcomes:
Antidepressants versus placebo for panic disorder in adults
1. Withdrawn From Research Study 2. Panic 3. Treatment Failure 4. Withdrawal Due To Adverse Events
outcomes:
Withdrawal versus continuation of long‐term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia
1. Cognitive function 2. Dementia Symptoms - Behavioral And Psychiatric 3. Quality of Life 4. Death 5. Clinical Finding 6. Clinical Global Impression 7. Adverse Event 8. Physical Restraint
outcomes:
Calcium channel blockers for antipsychotic‐induced tardive dyskinesia
1. Withdrawn From Research Study 2. Extrapyramidal Sign 3. Mental State Finding 4. Tardive dyskinesia
outcomes:
Cholinergic medication for antipsychotic‐induced tardive dyskinesia
1. Withdrawn From Research Study 2. Cognitive function 3. Costs and Cost Analysis 4. Extrapyramidal Sign 5. Aggressive Behavior 6. Agitated 7. Mental State Finding 8. Hospitalization 9. Tardive dyskinesia 10. Dystonia 11. Global Assessment 12. Social inclusion
outcomes:
Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia
1. Parkinsonism 2. Extrapyramidal Sign 3. Akathisia 4. Tardive dyskinesia 5. Dystonia 6. Adverse Event
outcomes:
Selective noradrenaline reuptake inhibitors for schizophrenia
1. Cognitive function 2. Quality of Life 3. Mental State Finding 4. Nausea 5. Global Assessment
outcomes:
Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse
1. Parkinsonism 2. Movement Disorder 3. Drug Craving 4. Withdrawn From Research Study 5. General well-being 6. Mental state 7. Finding Related To Substance Use 8. Schedule for Affective Disorders and Schizophrenia 9. Adverse Event 10. Extrapyramidal Disease
outcomes:
Benzodiazepines for antipsychotic‐induced tardive dyskinesia
1. Extrapyramidal Sign 2. Tardive dyskinesia
outcomes:
Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia
1. Extrapyramidal Sign 2. Quality of Life 3. Mental State Finding 4. Tardive dyskinesia
outcomes:
Anticholinergic medication for antipsychotic‐induced tardive dyskinesia
1. Withdrawn From Research Study 2. Social Network 3. Social confidence 4. Mental State Finding 5. Tardive dyskinesia 6. Adverse Event 7. Social inclusion
outcomes:
Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation)
1. Movement Disorder 2. Costs and Cost Analysis 3. Tranquilisation 4. Asleep 5. Agitated 6. Adverse Event 7. Sleepiness
outcomes:
Benzodiazepines for psychosis‐induced aggression or agitation
1. Costs and Cost Analysis 2. Asleep 3. Extrapyramidal Sign 4. Evaluation Of Satisfaction With Healthcare 5. Sedation 6. Global Assessment
outcomes:
Zuclopenthixol dihydrochloride for schizophrenia
1. Withdrawn From Research Study 2. Duration Of Hospital Stay 3. Mental State Finding 4. Suicide 5. Global Assessment 6. Adverse Event 7. Functional ability 8. Natural Death
outcomes:
Chlorpromazine versus penfluridol for schizophrenia
1. Withdrawn From Research Study 2. Relapse 3. Extrapyramidal Sign 4. Death 5. Mental State Finding 6. Hospitalization 7. Readmission 8. Global Assessment
outcomes:
Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation)
1. Tranquilisation 2. Serious Adverse Event 3. Cardiovascular observations 4. Costs and Cost Analysis 5. Asleep 6. Central Nervous System Diagnostic Radiopharmaceuticals 7. Benzodiazepine 8. Administration Of Tranquilizer 9. Seizure 10. Low Blood Pressure 11. Dystonia 12. Global Assessment
outcomes:
Vortioxetine for depression in adults
1. Withdrawn From Research Study 2. Treatment Failure 3. Drug Tolerance 4. Major Depression In Remission 5. Depressive symptoms 6. Withdrawal Due To Adverse Events 7. Major depressive disorder 8. Therapeutic Response
outcomes:
Antipsychotic combinations for schizophrenia
1. Withdrawn From Research Study 2. Serious Adverse Event 3. Short Form Health Survey - 36 4. Subjective Well-being under Neuroleptic Treatment Scale 5. Hospitalization 6. Assessment Using Clinical Outcomes In Routine Evaluation Outcome Measure
outcomes:
Communication skills training for mental health professionals working with people with severe mental illness
1. Duration Of Hospital Stay 2. Hospitalization 3. Global Assessment 4. Positive And Negative Syndrome Scale 5. Patient Satisfaction 6. Clinical Improvement
outcomes:
Assistive technology for memory support in dementia
1. Activities of Daily Living 2. Finding Relating To Institutionalization
outcomes:
Chlorpromazine versus clotiapine for schizophrenia
1. Withdrawn From Research Study 2. Extrapyramidal Sign 3. Mental State Finding 4. Global Assessment 5. Adverse Event
outcomes:
Chlorpromazine versus metiapine for schizophrenia
1. Movement Disorder 2. Parkinsonism 3. Aggressive Behavior 4. Behavior 5. Mental State Finding 6. Readmission 7. Global Assessment 8. Violent behaviour 9. Patient Satisfaction 10. Clinical Improvement
outcomes:
Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia
1. Withdrawn From Research Study 2. Duration Of Hospital Stay 3. Hospitalization 4. Brief Psychiatric Rating Scale - 1962 5. Weight Gain 6. Global Assessment 7. Patient Satisfaction
outcomes:
Compulsory community and involuntary outpatient treatment for people with severe mental disorders
1. Homeless 2. Psychiatric Symptom 3. Violence 4. Victimization 5. Duration Of Hospital Stay 6. Hospitalization 7. Social functioning 8. Global Assessment 9. Patient compliance 10. Patient Satisfaction 11. Patient-Reported Outcome
outcomes:
Risperidone versus placebo for schizophrenia
1. Withdrawn From Research Study 2. Extrapyramidal Sign 3. Hospitalization 4. Mental State Finding 5. Global Assessment
outcomes:
Implementation of treatment guidelines for specialist mental health care
1. Attitude 2. Patient compliance 3. ZUF-8 4. Positive And Negative Syndrome Scale 5. Patient Satisfaction 6. Patient-Reported Outcome
outcomes:
Droperidol for psychosis‐induced aggression or agitation
1. Hospital discharge 2. Costs and Cost Analysis 3. Serious Adverse Event 4. Tranquilisation 5. Cardiovascular observations 6. Cardiac Arrhythmia 7. Asleep 8. Aggressive Behavior 9. Mental State Finding 10. Respiratory finding 11. Global Assessment 12. Airways Obstruction
outcomes:
Haloperidol for long‐term aggression in psychosis
1. Withdrawn From Research Study 2. Tranquilisation 3. Serious Adverse Event 4. Costs and Cost Analysis 5. Aggressive Behavior 6. Self Inflicted Injury 7. Injury to others
outcomes:
Haloperidol plus promethazine for psychosis‐induced aggression
1. Hospital discharge 2. Costs and Cost Analysis 3. Serious Adverse Event 4. Sleep Finding 5. Aggressive Behavior 6. Death 7. Secluding Patient 8. Global Assessment 9. Adverse Event 10. Physical Restraint
outcomes:
Valproate for schizophrenia
1. Aggressive Behavior 2. Quality of Life 3. Agitated 4. Sedation 5. Weight Gain
outcomes:
Antihypertensive withdrawal for the prevention of cognitive decline
1. Blood pressure measurement 2. Cognitive function 3. Medication adherence 4. Adverse Event 5. Cognitive impairment
outcomes:
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults
1. Panic Disorder With Agoraphobia And Panic Attacks In Full Remission 2. Withdrawal Due To Adverse Events 3. Panic Disorder Without Agoraphobia With Panic Attacks In Full Remission 4. Therapeutic Response 5. Clinical Improvement
outcomes:
Bifeprunox versus placebo for schizophrenia
1. Relapse 2. Costs and Cost Analysis 3. Quality of Life 4. Mental State Finding 5. Readmission 6. Global Assessment 7. Adverse Event 8. Clinical Improvement
outcomes:
Psychological therapies for children and adolescents exposed to trauma
1. Posttraumatic Stress Disorder
outcomes:
Continuation and maintenance treatments for depression in older people
1. Recurrent Depression 2. Withdrawal Due To Adverse Events
outcomes:
Topiramate for acute affective episodes in bipolar disorder in adults
1. Bipolar Affective Disorder, Current Episode Mixed 2. Adverse Drug Reaction 3. Bipolar Affective Disorder, Current Episode Depression 4. Bipolar Affective Disorder, Current Episode Manic 5. Therapeutic Response 6. Bipolar Disorder In Remission
outcomes:
Cognitive behavioural therapy (CBT), third‐wave CBT and interpersonal therapy (IPT) based interventions for preventing depression in children and adolescents
1. Depression 2. Depressive symptoms
outcomes:
Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults
1. Mental Health Treatment 2. Costs and Cost Analysis 3. Referral To Mental Health Team 4. Self-harm 5. Drug Therapy 6. Quality of Life 7. Assessment Using Social Functioning Scale 8. Suicide 9. Clinical Improvement
outcomes:
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
1. Withdrawn From Research Study 2. Relapse 3. Costs and Cost Analysis 4. Extrapyramidal Sign 5. Quality of Life 6. Brief Psychiatric Rating Scale - 1962 7. Clinical Global Impression
outcomes:
Pharmacological interventions for clozapine‐induced sinus tachycardia
1. Heart Rate 2. Duration Of Hospital Stay 3. Adverse Event 4. Pulse Rate 5. Patient Satisfaction
outcomes:
Psychosocial interventions for self‐harm in adults
1. Self-harm 2. Readmission
outcomes:
Chlorpromazine versus reserpine for schizophrenia
1. Self-care Behavior 2. Mental State Finding 3. Toxic reaction 4. Global Assessment 5. Adverse Event
outcomes:
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta‐analysis
1. Withdrawn From Research Study 2. Panic Disorder With Agoraphobia And Panic Attacks In Full Remission 3. Therapeutic Response 4. Panic Disorder Without Agoraphobia With Panic Attacks In Full Remission 5. Clinical Improvement
outcomes:
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
1. Relapse 2. Extrapyramidal Sign 3. Mental State Finding 4. Generic Quality of Life Inventory 5. Clinical Improvement
outcomes:
Psychological therapies for post‐traumatic stress disorder and comorbid substance use disorder
1. Substance Misuse Behavior 2. Cooperative With Medical Treatment 3. Posttraumatic Stress Disorder 4. Substance Misuse Decreased
outcomes:
Therapist‐supported Internet cognitive behavioural therapy for anxiety disorders in adults
1. Quality of Life 2. Anxiety 3. Anxiety Symptoms 4. Adverse Event 5. Patient Satisfaction 6. Clinical Improvement
outcomes:
Interventions for preventing delirium in hospitalised non‐ICU patients
1. Delirium 2. Postoperative Complication 3. Infection 4. Falls 5. Cardiac Failure 6. Pressure ulcer 7. Death 8. Adverse Event
outcomes:
Antiglucocorticoid and related treatments for psychosis
1. Psychosis 2. Quality of Life 3. Depression 4. Global Assessment 5. Adverse Event
outcomes:
Statins for the prevention of dementia
1. Vascular Dementia 2. Mini Mental State Examination 3. Dementia Due To Alzheimer's Disease 4. Dementia
outcomes:
Zuclopenthixol versus placebo for schizophrenia
1. Withdrawn From Research Study 2. Relapse 3. Sedation 4. Global Assessment 5. Patient Satisfaction
outcomes:
Pharmacotherapy for chronic cognitive impairment in traumatic brain injury
1. Cognitive function 2. Neuropsychological Testing 3. Safety Finding 4. Clinical Finding 5. Clinical Global Impression 6. Patient Satisfaction
outcomes:
Asenapine versus placebo for schizophrenia
1. Withdrawn From Research Study 2. Serious Adverse Event 3. Mental State Finding 4. Global Assessment
outcomes:
Lithium for schizophrenia
1. Kidney disease 2. Relapse 3. Monitoring Response To Treatment 4. Thyroid Dysfunction 5. Acceptability of treatment
outcomes:
Cognitive behavioural therapy (brief versus standard duration) for schizophrenia
1. Withdrawn From Research Study 2. Quality of Life 3. Mental State Finding 4. Global Assessment 5. Clinical Improvement
outcomes:
Rivastigmine for Alzheimer's disease
1. Activities of Daily Living 2. Cognitive function 3. Withdrawn From Research Study 4. Dementia Symptoms - Behavioral And Psychiatric 5. Dependence 6. Quality of Life 7. Carer Able To Cope 8. Death 9. Clinical Finding 10. Clinical Global Impression 11. Finding Relating To Institutionalization
outcomes:
Endoscopic third ventriculostomy (ETV) for idiopathic normal pressure hydrocephalus (iNPH)
1. Postoperative Complication 2. Infection 3. Cerebrospinal Fluid Leak 4. Surgery 5. Death 6. Clinical Finding
outcomes:
Individual psychological therapy in the outpatient treatment of adults with anorexia nervosa
1. Treatment Withdrawal 2. Anorexia Nervosa In Remission 3. Body weight 4. Treatment Failure
outcomes:
Treatments for delusional disorder
1. Relapse 2. Delusions 3. Hospital admission 4. Beck Anxiety Inventory 5. Depression 6. Hospitalization 7. Social functioning 8. Clinical Improvement 9. Withdrawn From Research Study 10. Assessment Of Self Esteem 11. Anxiety 12. Withdrawal Due To Adverse Events 13. Beck Depression Inventory
outcomes:
Opioids for agitation in dementia
1. Dry Mouth 2. Functional Hallucinations 3. Nausea And Vomiting 4. Agitated 5. Safety Finding 6. Mood 7. Quality of Life 8. Sedated 9. Death 10. Carer Able To Cope 11. Adverse Event 12. Confusional State
outcomes:
Augmentation of cognitive and behavioural therapies (CBT) with d‐cycloserine for anxiety and related disorders
1. Treatment Withdrawal 2. Quality of Life 3. Anxiety Disorder 4. Depressive symptoms 5. Anxiety Symptoms 6. Therapeutic Response 7. Clinical Improvement
outcomes:
Psychoeducation for siblings of people with severe mental illness
1. Withdrawn From Research Study 2. Duration Of Hospital Stay 3. Mental State Finding 4. Hospitalization 5. Social functioning
outcomes:
Aerobic exercise to improve cognitive function in older people without known cognitive impairment
1. Cognitive function
outcomes:
Latrepirdine for Alzheimer's disease
1. Cognitive function 2. Safety Finding 3. Carer Able To Cope 4. Finding Relating To Institutionalization 5. Activities of Daily Living 6. Healthcare costs 7. Functionally Independent 8. Dementia Symptoms - Behavioral And Psychiatric 9. Quality of Life 10. Mood 11. Death 12. Clinical Finding 13. Clinical Global Impression
outcomes:
Debriefing interventions for the prevention of psychological trauma in women following childbirth
1. Treatment Withdrawal 2. Tocophobia 3. Psychological Trauma 4. Psychological Finding 5. Depressive symptoms 6. Depression 7. Anxiety 8. Health Care Utilization
outcomes:
Psychoeducation (brief) for people with serious mental illness
1. Relapse 2. Assessment Of Compliance With Medication Regimen 3. Death 4. Mental State Finding 5. Generic Quality of Life Inventory 6. Social functioning
outcomes:
Perphenazine for schizophrenia
1. Relapse 2. Costs and Cost Analysis 3. Serious Adverse Event 4. Extrapyramidal Sign 5. Death 6. Hospitalization 7. Global Assessment
outcomes:
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
1. Activities of Daily Living 2. Cognitive function 3. Behavior 4. Quality of Life 5. Caregiver Role Strain 6. Death 7. Disease Condition Finding 8. Clinical Global Impression 9. Adverse Event 10. Finding Relating To Institutionalization
outcomes:
Cognitive behavioural therapy for anxiety disorders in children and adolescents
1. Alleviating Anxiety 2. Anxiety Disorder 3. Lost To Clinical Trial Follow-up 4. Remission
outcomes:
Fluphenazine decanoate (depot) and enanthate for schizophrenia
1. Withdrawn From Research Study 2. Relapse 3. All Cause Mortality 4. Death 5. Mental State Finding 6. Hospitalization 7. Brief Psychiatric Rating Scale - 1962 8. Tardive dyskinesia 9. Global Assessment
outcomes:
Pharmacotherapy for anxiety and comorbid alcohol use disorders
1. Heavy Drinking Session 2. Alcoholism 3. Anxiety Disorder 4. Depressive symptoms 5. Anxiety 6. Alcoholic Drink 7. Withdrawal Due To Adverse Events 8. Therapeutic Response 9. Abstinent Alcoholic
outcomes:
Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
1. Withdrawn From Research Study 2. Global Assessment 3. Adverse Event 4. Therapeutic Response
outcomes:
Antidepressant treatment for postnatal depression
1. Major Depression In Remission 2. Depression 3. Adverse Event 4. Therapeutic Response
outcomes:
Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia
1. Therapeutic Response
outcomes:
Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia
1. Movement Disorder 2. Withdrawn From Research Study 3. Death 4. Acceptability of treatment 5. Sedation 6. Adverse Event 7. Therapeutic Response
outcomes:
Alternating current cranial electrotherapy stimulation (CES) for depression
1. Hamilton Rating Scale For Depression 2. Depression 3. Montgomery Asberg Depression Rating Scale 4. Withdrawal Due To Adverse Events 5. Beck Depression Inventory
outcomes:
Pharmacological interventions for preventing post‐traumatic stress disorder (PTSD)
1. Posttraumatic Stress Disorder 2. Efficacy 3. Withdrawal Due To Adverse Events
outcomes:
Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders
1. Movement Disorder 2. Withdrawn From Research Study 3. Relapse 4. Costs and Cost Analysis 5. Hospital admission 6. Clinical Outcome
outcomes:
Pericyazine for schizophrenia
1. Clinical Global Impression 2. Adverse Event
outcomes:
Carbamazepine for schizophrenia
1. Aggressive Behavior 2. Depression 3. Brief Psychiatric Rating Scale - 1962 4. Positive And Negative Syndrome Scale
outcomes:
Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression
1. Duration of Symptom 2. Depressive Disorder In Remission 3. Aspiration 4. Hamilton Rating Scale For Depression 5. Cardiac Arrest 6. Depression 7. Seizure 8. Anesthetic Allergy 9. Time-to-Event 10. Clinical Improvement
outcomes:
Sulpiride versus placebo for schizophrenia
1. Clinical Global Impression
outcomes:
General physical health advice for people with serious mental illness
1. Quality Of Life Scale 2. Withdrawn From Research Study 3. Costs and Cost Analysis 4. Disease Related State 5. Quality of Life 6. Health Behavior 7. Adverse Event 8. Health awareness
outcomes:
Metal protein attenuating compounds for the treatment of Alzheimer's dementia
1. Activities of Daily Living 2. Cognitive function 3. Quality of Life 4. Biomarker analysis 5. Carer Able To Cope 6. Death 7. Clinical Finding 8. Clinical Global Impression 9. Adverse Event
outcomes:
Physical health care monitoring for people with serious mental illness
1. Quality of Life 2. Assessment Of Physical Health
outcomes:
Respite care for people with dementia and their carers
1. Activities of Daily Living 2. Cognitive function 3. Abuse 4. Dementia Symptoms - Behavioral And Psychiatric 5. Quality of Life 6. Death 7. Finding Relating To Institutionalization
outcomes:
Perazine for schizophrenia
1. Movement Disorder 2. Drug Tolerance 3. Mental State Finding 4. Clinical Global Impression 5. Therapeutic Response
outcomes:
Chlorpromazine versus placebo for schizophrenia
1. Withdrawn From Research Study 2. Relapse 3. Costs and Cost Analysis 4. Behavior 5. Death 6. Global Assessment 7. Patient Satisfaction
outcomes:
Aripiprazole versus other atypical antipsychotics for schizophrenia
1. Withdrawn From Research Study 2. Extrapyramidal Sign 3. Quality of Life Inventory 4. Brief Psychiatric Rating Scale - 1962 5. Global Assessment 6. Adverse Event 7. Functional ability
outcomes:
Anticholinergic medication for non‐clozapine neuroleptic‐induced hypersalivation in people with schizophrenia
1. Excessive Salivation 2. Adverse Event 3. Clinical Improvement
outcomes:
Agomelatine versus other antidepressive agents for major depression
1. Hamilton Rating Scale For Depression 2. Depression 3. Major Depression In Remission
outcomes:
Quetiapine versus other atypical antipsychotics for schizophrenia
1. Clinical Global Impression
outcomes:
Haloperidol versus placebo for schizophrenia
1. Parkinsonism 2. Withdrawn From Research Study 3. Hospital discharge 4. Relapse 5. All Cause Mortality 6. Non-affective psychosis 7. Behavior 8. Death 9. Suicide 10. Patient Satisfaction 11. Clinical Improvement
outcomes:
Pimozide for schizophrenia or related psychoses
1. Extrapyramidal Sign 2. Mental State Finding 3. Clinical Global Impression
outcomes:
Dietary supplements for preventing postnatal depression
1. Edinburgh Postnatal Depression Scale 2. Postpartum Depression
outcomes:
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder
1. Hospital admission 2. Mania 3. Depression
outcomes:
Atypical antipsychotics for psychosis in adolescents
1. Global Assessment Of Functioning 2. Health Services Utilization 3. Clinical Global Impression 4. Adverse Event 5. Therapeutic Response
outcomes:
Exercise for depression
1. Hamilton Rating Scale For Depression 2. Quality of Life 3. Depression 4. Adverse Event 5. Beck Depression Inventory
outcomes:
Driving assessment for maintaining mobility and safety in drivers with dementia
1. Patient Should Not Drive Or Operate Machinery 2. Motor Vehicle Accident, Driver
outcomes:
Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia
1. Activities of Daily Living 2. Cognitive function 3. Behavior 4. Mood 5. Quality of Life 6. Biomarker analysis 7. Carer Able To Cope 8. Disease Condition Finding
outcomes:
Flow‐regulated versus differential pressure‐regulated shunt valves for adult patients with normal pressure hydrocephalus
1. Quality of Life 2. Death 3. Disease Condition Finding 4. Adverse Event
outcomes:
Rivastigmine for vascular cognitive impairment
1. Activities of Daily Living 2. Cognitive function 3. Dementia Symptoms - Behavioral And Psychiatric 4. Safety Finding 5. Carer Able To Cope 6. Death 7. Clinical Finding 8. Clinical Global Impression
outcomes:
Quetiapine versus typical antipsychotic medications for schizophrenia
1. Clinical Global Impression
outcomes:
Intermittent phototherapy versus continuous phototherapy for neonatal jaundice
1. Bilirubin-induced brain dysfunction 2. Serum Bilirubin level 3. Death
outcomes:
Volume‐targeted versus pressure‐limited ventilation in neonates
1. Pneumothorax 2. Intraventricular Hemorrhage 3. Pulmonary Air Leakage 4. Periventricular Leukomalacia 5. Pulmonary Interstitial Emphysema Syndrome 6. Neurological Muscular Paralysis 7. Oxygen Supplementation 8. Ventilatory Failure 9. Respiratory Acidosis 10. Bronchopulmonary Dysplasia Of Newborn 11. Death 12. Mechanical ventilation 13. Fraction Of Inspired Oxygen 14. Patent Ductus Arteriosus
outcomes:
Early planned removal of umbilical venous catheters to prevent infection in newborn infants
1. All Cause Mortality 2. Removal Of Catheter 3. Catheter site thrombosis 4. Infection Of Bloodstream
outcomes:
Cerebral near‐infrared spectroscopy monitoring for prevention of brain injury in very preterm infants
1. All Cause Mortality 2. Blindness - Both Eyes 3. Intraventricular Hemorrhage 4. Retinopathy Of Prematurity 5. Bayley Scale Of Infant Development 6. Bronchopulmonary Dysplasia Of Newborn 7. Necrotizing Enterocolitis 8. Periventricular Leukomalacia 9. Cerebral Palsy 10. Adverse Event 11. Patent Ductus Arteriosus 12. Neurodevelopmental Delay
outcomes:
Sildenafil for pulmonary hypertension in neonates
1. All Cause Mortality 2. Hemodynamic test 3. Hospitalization 4. Oxygenation Monitoring 5. Cardiac output 6. Pulmonary arterial pressure 7. Mean Arterial Pressure 8. Partial Arterial Pressure Of Oxygen
outcomes:
Fluid supplementation for neonatal unconjugated hyperbilirubinaemia
1. Kernicterus Of Newborn 2. Neurological Findings Abnormal 3. Exchange Transfusion 4. Bilirubin 5. Cerebral Palsy 6. Breastfeeding
outcomes:
Saline irrigation for the management of skin extravasation injury in neonates
1. Wound healing
outcomes:
Antibiotics for neonates born through meconium‐stained amniotic fluid
1. Death 2. Sepsis 3. Duration Of Hospital Stay 4. Respiratory Failure 5. Mechanical ventilation 6. Meconium Aspiration Syndrome 7. Oxygen Therapy
outcomes:
Orotracheal intubation in infants performed with a stylet versus without a stylet
1. Body weight 2. Treatment Success 3. Orotracheal Intubation 4. Gestational Age 5. Stylet
outcomes:
Clonidine for sedation and analgesia for neonates receiving mechanical ventilation
1. Neonatal Death 2. Mechanical ventilation
outcomes:
Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants
1. Disability 2. Retinopathy Of Prematurity 3. Blindness 4. Necrotizing Enterocolitis 5. Death
outcomes:
Repeated lumbar or ventricular punctures in newborns with intraventricular haemorrhage
1. Infection 2. Disability 3. Ventriculoperitoneal Shunt 4. Hydrocephalus 5. Death 6. Neonatal Death 7. Neurodevelopmental Disorder 8. Neurodevelopmental Delay
outcomes:
Frenotomy for tongue‐tie in newborn infants
1. Visual Analog Pain Scale 2. Short Form Mcgill Pain Questionnaire 3. Nipple Pain 4. Breast Fed 5. LATCH 6. Infant Breastfeeding Assessment Tool 7. Haemorrhage
outcomes:
Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in low and middle income countries
1. Bulging Fontanelle 2. Vomiting 3. Death 4. Vitamin A Deficiency 5. Diarrhoea
outcomes:
Skin‐to‐skin care for procedural pain in neonates
1. Gross Movement Of Body And Limbs 2. Heart Rate 3. Pain 4. Respiratory Rate 5. Pain Scale 6. Grimaces 7. Crying 8. Oxygen Saturation 9. Cortisol level
outcomes:
Topical anaesthesia for needle‐related pain in newborn infants
1. Pain 2. Pain Scale 3. Skin Reaction 4. Device Complication 5. Venipuncture 6. Adverse Event 7. Intravenous Catheter Management
outcomes:
Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit
1. Blood pressure measurement 2. Respiratory Rate 3. Pain Scale 4. Plasma Cortisol 5. Excitability 6. Neonatal Death 7. Grimaces 8. Catecholamine level 9. Muscle Tone 10. Pain 11. Behavior 12. Neurological Finding 13. Duration Of Hospital Stay 14. Alteration In Heart Rate 15. Respiratory finding 16. Intensive Care 17. Oxygen Saturation
outcomes:
Cromolyn sodium for the prevention of chronic lung disease in preterm infants
1. Chronic Lung Disease 2. Death 3. Mechanical ventilation
outcomes:
Body positioning for spontaneously breathing preterm infants with apnoea
1. Bradycardia 2. Apnea 3. Neonatal Oxygen Desaturation
outcomes:
Nitric oxide for respiratory failure in infants born at or near term
1. Extracorporeal Membrane Oxygenation 2. Disease Progression 3. Death 4. Neurodevelopmental Disorder 5. Neurodevelopmental Delay
outcomes:
Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates
1. Chronic Lung Disease 2. Death 3. Dependence On Supplemental Oxygen
outcomes:
Inhaled nitric oxide for respiratory failure in preterm infants
1. Intraventricular Hemorrhage 2. Bronchopulmonary Dysplasia Of Newborn 3. Death 4. Neurodevelopmental Delay
outcomes:
Heparin for the treatment of thrombosis in neonates
1. Treatment Failure 2. Death
outcomes:
Infant position in neonates receiving mechanical ventilation
1. Catheter Dislodgment 2. Pulse Oximetry 3. Pneumothorax 4. Ventilator Associated Pneumonia 5. Chronic Lung Disease 6. Intraventricular Hemorrhage 7. Device Dislodgement 8. Neonatal Oxygen Desaturation 9. Pulmonary Interstitial Emphysema Syndrome 10. Carbon Dioxide Measurement 11. Lung function test 12. Neurodevelopmental Delay 13. Partial Arterial Pressure Of Oxygen 14. Airway peak pressure 15. Inadvertent Tracheal Extubation 16. Bronchopulmonary Dysplasia Of Newborn 17. Death 18. Oxygen Saturation 19. Mechanical ventilation 20. Fraction Of Inspired Oxygen 21. Perinatal Periventricular Hemorrhage
outcomes:
Synchronized mechanical ventilation for respiratory support in newborn infants
1. Pneumothorax 2. Weaning From Mechanically Assisted Ventilation 3. Intraventricular Hemorrhage 4. Pulmonary Air Leakage 5. Bronchopulmonary Dysplasia Of Newborn 6. Dependence On Respirator 7. Death 8. Pulmonary Interstitial Emphysema Syndrome 9. Dependence On Supplemental Oxygen
outcomes:
Responsive versus scheduled feeding for preterm infants
1. Weight change 2. Normal Growth 3. Head Circumference 4. Hospitalization 5. Weight Gain 6. Height and growth measurements 7. Infant Feeding Method 8. Skinfold Measurement
outcomes:
Cup feeding versus other forms of supplemental enteral feeding for newborn infants unable to fully breastfeed
1. Hospitalization 2. Breastfeeding Problem In The Newborn 3. Weight Gain
outcomes:
Early additional food and fluids for healthy breastfed full‐term infants
1. Infant Death 2. Jaundice 3. Food Allergy 4. Hypoglycemia 5. Enterocolitis 6. Fever 7. Allergies 8. Self-confidence Finding 9. Confident 10. Morbidity Index 11. Weight change 12. Weight Loss 13. Eczema 14. Breast Fed 15. Self-efficacy assessment 16. Breastfeeding
outcomes:
Instruments for assessing readiness to commence suck feeds in preterm infants: effects on time to establish full oral feeding and duration of hospitalisation
1. Hospitalization 2. Infant Feeding Method
outcomes:
Sucrose for analgesia in newborn infants undergoing painful procedures
1. Pain 2. Pain Scale 3. Neurodevelopmental Delay
outcomes:
Epinephrine for transient tachypnea of the newborn
1. Mechanical ventilation 2. Oxygen Supplementation
outcomes:
Heparin for the prevention of intraventricular haemorrhage in preterm infants
1. Intraventricular Hemorrhage 2. Neonatal Death
outcomes:
Co‐bedding in neonatal nursery for promoting growth and neurodevelopment in stable preterm twins
1. Infection 2. Neonatal Desaturation Spells 3. Developing Organized Infant Behavior 4. Bradycardia 5. Apnea 6. Hospitalization 7. Weight Gain
outcomes:
Antimicrobial dressings for the prevention of catheter‐related infections in newborn infants with central venous catheters
1. Sepsis 2. Death 3. Dermatitis 4. Central Venous Catheter Related Bloodstream Infection 5. Bacterial Colonization
outcomes:
Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants
1. Intraventricular Hemorrhage 2. Death 3. Neonatal Death
outcomes:
Frequency of endotracheal suctioning for the prevention of respiratory morbidity in ventilated newborns
1. Chronic Lung Disease 2. Mechanical ventilation 3. Oxygen Supplementation
outcomes:
Transcutaneous carbon dioxide monitoring for the prevention of neonatal morbidity and mortality
1. Chronic Lung Disease 2. Sensorineural Hearing Loss 3. Intellect Impaired 4. Blindness 5. Developmental Delay 6. Neonatal Death 7. Cerebral Palsy 8. Mechanical ventilation 9. Neurodevelopmental Delay 10. Oxygen Supplementation
outcomes:
Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants
1. Parenteral Nutrition Associated Liver Disease 2. Chronic Lung Disease 3. Neonatal Death 4. Neurodevelopmental Delay 5. Retinopathy Of Prematurity 6. Hypertriglyceridemia 7. Bronchopulmonary Dysplasia Of Newborn 8. Sepsis 9. Death 10. Weight Gain 11. Height and growth measurements 12. Mechanical ventilation 13. Cholestasis
outcomes:
Diuretics for transient tachypnoea of the newborn
1. Transitory Tachypnea Of Newborn 2. Weight Loss 3. Continuous Positive Airway Pressure Ventilation 4. Hospitalization 5. Mechanical ventilation 6. Oxygen Supplementation 7. Patent Ductus Arteriosus
outcomes:
Chest shielding for prevention of a haemodynamically significant patent ductus arteriosus in preterm infants receiving phototherapy
1. Patent Ductus Arteriosus
outcomes:
Specialist teams for neonatal transport to neonatal intensive care units for prevention of morbidity and mortality
1. Death